FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Marketing

FDA Sued Over Rejection of Supplement Ad Claims

Three Benesh Friedlander Coplan & Aronoff attorneys say a suit against FDA filed by the Alliance for Natural Health USA could change the way that supp...

Medical Devices

BMC Medical Selling Adulterated, Misbranded CPAPs: FDA

FDA warns Chinas BMC Medical that it is marketing adulterated and misbranded ventilators in the U.S. without an approved PMA in place for the devices....

Human Drugs

FDA OKs Casgevy for Younger Children

FDA approves an expanded age indication for Vertex Pharmaceuticals sickle cell drug Casgevy.

Medical Devices

Quality System, Other Violations at 3B Medical

FDA warns 3B Medical about multiple violations in its work manufacturing a software device used with ventilator systems imported from China.

Medical Devices

AseptiKits Marketing Adulterated, Misbranded Devices: FDA

FDA warns AseptiKits it is manufacturing and marketing adulterated and misbranded PALA Your Tears medical devices.

Human Drugs

FDA Approves BESREMi Pen for Polycythemia Vera

FDA approves PharmaEssentias BESREMi injection pen to treat polycythemia vera.

latest-news-card-1
Human Drugs

OAI Inspections at U.S. Drug Sites Surpassed India in 2025: Analysis

A new analysis of FDA inspection data suggests pharmaceutical manufacturing facilities in the U.S. received a higher proportion of the agency's most s...

latest-news-card-1
Biologics

Capricor's Duchenne Cell Therapy Set for Advisory Committee Review

FDA informs Capricor Therapeutics that it has scheduled an advisory committee meeting to review the company's BLA resubmission for deramiocel, an inve...

latest-news-card-1
Human Drugs

Dr. Reddy's Gets 7-Item FDA Form 483 After Biologics Inspection

FDA cites Dr. Reddy's Laboratories in a seven-observation Form 483 following a recent pre-license inspection of its biologics manufacturing facility i...

latest-news-card-1
Human Drugs

Lantheus Gets Complete Response Letter for Tumor Imaging Agent

FDA issues Lantheus a Complete Response Letter for its NDA seeking approval for LNTH-2501 (gallium-68 edotreotide), a positron emission tomography ima...